MAUDE Adverse Event Report: TERUMO BCT SPECTRA OPTIA; SPECTRA OPTIA IDL SET

Catalog Number 10310

Device Problems No Apparent Adverse Event (3189); Insufficient Information (3190)

Patient Problem Hypersensitivity/Allergic reaction (1907)

Event Date 06/27/2023

Event Type  Injury  

Manufacturer Narrative

Lot number and expiry information are not available at this time.Investigation is in process, a follow-up report will be provided.Bubar, r., kiss, j. e., triulzi, d. j., d'andrea, p., zilich, a., & kaplan, a.(2023).How do we¿consistently provide high-dose granulocyte products for transfusions in neutropenic patients? transfusion, 63(7), 1267-1276. https://doi.Org/10.1111/trf.17461.

Event Description

Per journal article "how do we.Consistently provide high-dose granulocyte products for transfusions in neutropenic patients? transfusion.2023." by authors: bubar, r.,kiss, j.E.,triulzi, d.J.,d'andrea, p.,zilich, a.,kaplan, a.There were adverse events that occurred during granulocyte procedures that included local hematoma, moderate citrate reaction, and a bag failures the citrate reaction was treated with oral calcium carbonate and reducing the anticoagulant to the donor.The collection set is not available for return because it was discarded by the customer.Specific details, such as patient information and outcome, were not included in the article for these events, therefore this report is being provided as a summary of the events.

Event Description

Per journal article "how do we.Consistently provide high-dose granulocyte products for transfusions in neutropenic patients? transfusion.2023." by authors: bubar, r.,kiss, j.E.,triulzi, d.J.,d'andrea, p.,zilich, a.,kaplan, a.There were adverse events that occurred during granulocyte procedures that included local hematoma, moderate citrate reaction, and a bag failures the citrate reaction was treated with oral calcium carbonate and reducing the anticoagulant to the donor.The collection set is not available for return because it was discarded by the customer.Specific details, such as patient information and outcome, were not included in the article for these events, therefore this report is being provided as a summary of the events.

Manufacturer Narrative

This report is being filed to provide additional information in investigation: further evaluation of this event has determined that the device did not cause or contribute to a death or serious injury, nor is there a likely potential for death or serious injury associated with this event based on additional investigational information.It was confirmed that only oral calcium was given for the citrate reactions.No further reporting will be provided as this does not represent a reportable event.The effectiveness of granulocyte transfusions in neutropenic patients has been difficult to assess, in part due to variations in product dosage.Data from randomized controlled trials suggest that transfused units should contain a minimum of 4.0 x 1010 granulocytes per unit.Here we describe a safe granulocyte collection procedure that has consistently produced high-dose units with low platelet and rbc contamination over a four-year period.Additionally, we demonstrate that transfusion of these units produces measurable neutrophil increments in adult patients.Since this was a retrospective chart review for apheresis granulocyte donations collected between 2018 and 2021 following implementation of combined g-csf and dexamethasone donor stimulation at an institution, the lot numbers were not requested; therefore, a disposable lot history search could not be conducted.Root cause: a root cause assessment was performed for the reported hematoma.Based on the available information a definitive root cause could not be determined but it is likely due to one or a combination of the possible causes listed below: * needle was out of position * poor phlebotomy * return flow rate was too high a root cause assessment was performed for the reported citrate reactions.These reactions occur due to decreased ionized calcium in circulation as a result of exogenous citrate administered during the apheresis procedure and are influenced by donor physiology, the rate of ac infusion, and/or the length of the procedure.These symptoms may be treated with oral or intravenous calcium supplements or by adjusting the ac infusion rate.A root cause assessment was performed for the reported bag leak.Based on the available information a definitive root cause could not be determined but it is likely due to one or a combination of the possible causes listed below: * an error in the rf welding so that a perimeter or tube/adapter leak occurs * a leak at a bonded connection due to an error in solvent application during manufacturing * an issue with the raw material bag vinyl from the supplier * damage to the bag related to handling during manufacturing or by the customer bubar, r., kiss, j. e., triulzi, d. j., d'andrea, p., zilich, a., & kaplan, a.(2023).How do we¿consistently provide high-dose granulocyte products for transfusions in neutropenic patients? transfusion, 63(7), 1267-1276. https://doi.Org/10.1111/trf.17461.

• Brand Name: SPECTRA OPTIA
• Type of Device: SPECTRA OPTIA IDL SET
• Manufacturer (Section D): TERUMO BCT; lakewood CO 80215
• Manufacturer (Section G): TERUMO BCT; 10810 w. collins ave; lakewood CO 80215
• Manufacturer Contact: scot hilden ; 10810 w. collins ave; lakewood, CO 80215
• MDR Report Key: 17452050
• MDR Text Key: 320320223
• Report Number: 1722028-2023-00266
• Device Sequence Number: 1
• Product Code: LKN
• Combination Product (y/n): N
• Reporter Country Code: US
• PMA/PMN Number: K183081
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Literature,Health Professional
• Reporter Occupation: Other Health Care Professional
• Type of Report: Initial,Followup
• Report Date: 08/03/2023

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Catalogue Number: 10310
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Initial Date Manufacturer Received: 07/10/2023
• Initial Date FDA Received: 08/03/2023
• Supplement Dates Manufacturer Received: 09/13/2023
• Supplement Dates FDA Received: 09/21/2023
• Was Device Evaluated by Manufacturer?: No
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Other